CTOs on the Move

RaceFan

www.racefan.com

 
RaceFan is a Birmingham, AL-based company in the Software and Internet sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.racefan.com
  • 5200 Cahaba River Rd
    Birmingham, AL USA 35243
  • Phone: 877.595.7223

Executives

Name Title Contact Details

Similar Companies

Koxa

Koxa’s API platform connects accounting software directly to corporate bank accounts

Wireless Innovations

Wireless Innovations is a company that provides productivity enhancing business solutions, including MDM services, Cradlepoint, highly customized e-procurement portals, and superior support. They are an exclusive T-Mobile partner with extensive knowled...

e4orce

e4orce is a Boston, MA-based company in the Software and Internet sector.

Brainshark

Brainshark was founded in 1999 with one vision: to transform the way businesspeople create and share content. From this vision, the Brainshark platform was born – enabling the average businessperson with only basic tools, like PowerPoint and the phone, to create high-impact video presentations that help lower costs and drive business value. Before the ideas of user-generated content, software-as-a-service and online video became standard practice, Brainshark was already pioneering these concepts to enhance business communications. Today, Brainshark helps thousands of companies around the world improve productivity with cloud-based business presentation solutions for sales, marketing and training.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.